Changing the Health Behavior of Patients With Cardiovascular Disease Through an Electronic Health Intervention in Three Different Countries: Cost-Effectiveness Study in the Do Cardiac Health: Advanced New Generation Ecosystem (Do CHANGE) 2 Randomized Controlled Trial

被引:13
作者
Piera-Jimenez, Jordi [1 ,2 ]
Winters, Marjolein [3 ]
Broers, Eva [4 ,5 ]
Valero-Bover, Damia [2 ]
Habibovic, Mirela [4 ,5 ]
Widdershoven, Jos W. M. G. [4 ,5 ]
Folkvord, Frans [1 ,6 ]
Lupianez-Villanueva, Francisco [1 ,7 ]
机构
[1] Univ Oberta Catalunya, Open Evidence Res Grp, Rambla Poblenou 156, Barcelona 08018, Spain
[2] Badalona Serveis Assistencials, Dept R&D, Badalona, Spain
[3] Smart Homes, Eindhoven, Netherlands
[4] Tilburg Univ, Dept Med & Clin Psychol, Tilburg, Netherlands
[5] Elisabeth TweeSteden Hosp, Dept Cardiol, Tilburg, Netherlands
[6] Tilburg Univ, Tilburg Sch Humanities & Digital Sci, Dept Commun & Cognit, Tilburg, Netherlands
[7] Univ Oberta Catalunya, Dept Informat & Commun Sci, Barcelona, Spain
基金
欧盟地平线“2020”;
关键词
cost-effectiveness; randomized controlled trial; RCT; eHealth; cardiovascular disease; engagement; behavior change; digital health; EQ-5D; TIME; PROGRAM; IMPACT; RISK;
D O I
10.2196/17351
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background: During the last few decades, preventing the development of cardiovascular disease has become a mainstay for reducing cardiovascular morbidity and mortality. It has been suggested that interventions should focus more on committed approaches of self-care, such as electronic health techniques. Objective: This study aimed to provide evidence to understand the financial consequences of implementing the "Do Cardiac Health: Advanced New Generation Ecosystem" (Do CHANGE 2) intervention, which was evaluated in a multisite randomized controlled trial to change the health behavior of patients with cardiovascular disease. Methods: The cost-effectiveness analysis of the Do CHANGE 2 intervention was performed with the Monitoring and Assessment Framework for the European Innovation Partnership on Active and Healthy Ageing tool, based on a Markov model of five health states. The following two types of costs were considered for both study groups: (1) health care costs (ie, costs associated with the time spent by health care professionals on service provision, including consultations, and associated unplanned hospitalizations, etc) and (2) societal costs (ie, costs attributed to the time spent by patients and informal caregivers on care activities). Results: The Do CHANGE 2 intervention was less costly in Spain (incremental cost was -(sic)2514.90) and more costly in the Netherlands and Taiwan (incremental costs were (sic)1373.59 and (sic)1062.54, respectively). Compared with treatment as usual, the effectiveness of the Do CHANGE 2 program in terms of an increase in quality-adjusted life-year gains was slightly higher in the Netherlands and lower in Spain and Taiwan. Conclusions: In general, we found that the incremental cost-effectiveness ratio strongly varied depending on the country where the intervention was applied. The Do CHANGE 2 intervention showed a positive cost-effectiveness ratio only when implemented in Spain, indicating that it saved financial costs in relation to the effect of the intervention.
引用
收藏
页数:18
相关论文
共 49 条
[31]   Spanish recommendations on economic evaluation of health technologies [J].
Lopez-Bastida, Julio ;
Oliva, Juan ;
Antonanzas, Fernando ;
Garcia-Altes, Anna ;
Gisbert, Ramon ;
Mar, Javier ;
Puig-Junoy, Jaume .
EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2010, 11 (05) :513-520
[32]   Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study [J].
McConnachie, Alex ;
Walker, Andrew ;
Robertson, Michele ;
Marchbank, Laura ;
Peacock, Julie ;
Packard, Christopher J. ;
Cobbe, Stuart M. ;
Ford, Ian .
EUROPEAN HEART JOURNAL, 2014, 35 (05) :290-298
[33]   Cost-effectiveness of a European preventive cardiology programme in primary care: a Markov modelling approach [J].
Mistry, Hema ;
Morris, Stephen ;
Dyer, Matthew ;
Kotseva, Kornelia ;
Wood, David ;
Buxton, Martin .
BMJ OPEN, 2012, 2 (05)
[34]   Negotiating the coresearcher mandate - service users' experiences of doing collaborative research on mental health [J].
Moltu, Christian ;
Stefansen, Jon ;
Svisdahl, Marit ;
Veseth, Marius .
DISABILITY AND REHABILITATION, 2012, 34 (19) :1608-1616
[35]   Cost-Effectiveness of Telemonitoring and Self-Monitoring of Blood Pressure for Antihypertensive Titration in Primary Care (TASMINH4) [J].
Monahan, Mark ;
Jowett, Sue ;
Nickless, Alecia ;
Franssen, Marloes ;
Grant, Sabrina ;
Greenfield, Sheila ;
Hobbs, F. D. Richard ;
Hodgkinson, James ;
Mant, Jonathan ;
McManus, Richard J. .
HYPERTENSION, 2019, 73 (06) :1231-1239
[36]  
National Institute for Health and Care Excellence (NICE), Recovered by removing the absolute value at the numerator of Eq.(E4)
[37]   Connected Health in Hypertension Management [J].
Omboni, Stefano .
FRONTIERS IN CARDIOVASCULAR MEDICINE, 2019, 6
[38]   IS THE CHOICE OF WILLINGNESS-TO-PAY THRESHOLD IN COST-UTILITY ANALYSIS ENDOGENOUS TO THE RESULTING VALUE OF THE TECHNOLOGY? [J].
Padula, W., V ;
Chen, H. B. ;
Phelps, C. E. .
VALUE IN HEALTH, 2018, 21 :S362-S362
[39]  
Piepoli MF, 2016, ATHEROSCLEROSIS, V252, P207, DOI [10.1016/j.atherosclerosis.2016.05.037, 10.1177/2047487316653709]
[40]   Mobile Health Devices as Tools for Worldwide Cardiovascular Risk Reduction and Disease Management [J].
Piette, John D. ;
List, Justin ;
Rana, Gurpreet K. ;
Townsend, Whitney ;
Striplin, Dana ;
Heisler, Michele .
CIRCULATION, 2015, 132 (21) :2012-2027